DifferentiatedsubcutaneouspreADIpocytesinculture.
ProductOverview:
Poietics™DiseasedHumanPreadipocytes(D-HprAD)areisolatedfromsubcutaneousorvisceralfatfromdiabeticTypeIanddiabeticTypeIIdonors.Preadipocytesfrom normal(non-diabetic)donorsareavailableasaseparateproduct.Pertinentadditionaldonorinformation,includingBodyMassIndex(BMI),insulindependence,andageofdiagnosismaybeavailablebycontactingScientificSupport.
CryopreservedPoietics™DiseasedHumanPreadipocytes(D-HprAD)areguaranteedtocontain≥1millioncellsperampouleandtestpositiveforAdipogenicdifferentiation.Allcellstestnegativeformycoplasma,bacteria,yeast,andfungi.HIV-1,hepatitisBandhepatitisCarenotdetectedforalldonorsand/orcelllots.ACertificateofAnalysisisprovidedforeachcelllotpurchased.
RecommendedMedium: PGM™-2PreadipocyteGrowthMedium-2BulletKit™Medium(providesbothaproliferationmediumandadifferentiationmediumguaranteedtoinducedifferentiationintomature,functionallyactiveadipocytes;EachbottleofthePGM-2™BulletKit™Mediumcontainsenoughdifferentiationmediumtofullydifferentiate10millionpreadipocytes[10complete96-wellplates]intomature,functionallyactiveadipocytes).
ThePGM™-2MediumisofferedasaBulletKit™Medium(catalogno.PT-8002)whichincludesboththebasalmediumandthenecessarysupplementsforbothproliferationanddifferentiationofpreadipocytes.Thebasalmedium(PGM™-2BasalMedium;catalogno.PT-8202)andthenecessarysupplements(PGM™-2SingleQuot™Kit;catalogno.PT-9502)canalsobepurchasedindividually.
LonzaguaranteestheperformanceofClonetics™/Poietics™cellsonlyifappropriateClonetics™/Poietics™mediaandreagentsareusedexclusivelyandtherecommendedstorageanduseprotocolsarefollowed.Anymodificationsmadetotherecommendedcellsystemsincludingtheuseofalternativemedia,reagentsorprotocols,willvoidcellandmediaperformanceguarantees.Ifyouneedassistanceinselectingtheappropriatemedia,reagents,orprotocol,pleasecontactLonzaScientificSupport.
